top of page

Access, Ideas, Clarity

A leading virtual platform providing investors with direct access to innovative companies, management teams and thought leaders

Sonnet_Logo_7.24.png

Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study

Contat Us
bottom of page